Company Description
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases.
The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system.
It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient’s body during and after treatment, known as Minimal Residual Disease (MRD).
The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications.
It has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers.
The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011.
Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.
| Country | United States |
| Founded | 2009 |
| IPO Date | Jun 27, 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 619 |
| CEO | Chad Robins |
Contact Details
Address: 1165 Eastlake Avenue East Seattle, Washington 98109 United States | |
| Phone | 206 659 0067 |
| Website | adaptivebiotech.com |
Stock Details
| Ticker Symbol | ADPT |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $20.00 |
| CIK Code | 0001478320 |
| CUSIP Number | 00650F109 |
| ISIN Number | US00650F1093 |
| Employer ID | 27-0907024 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Chad M. Robins M.B.A. | Co-Founder, Chief Executive Officer and Chairman |
| Julie Rubinstein | President and Chief Operating Officer |
| Dr. Harlan S. Robins Ph.D. | Co-Founder and Chief Scientific Officer |
| Kyle Piskel | Vice President, Chief Financial Officer and Principal Accounting Officer |
| Dr. Sharon Benzeno Ph.D. | Chief Commercial Officer of Immune Medicine |
| Christopher Carlson Ph.D. | Founder |
| Karina Calzadilla | Vice President of Investor Relations |
| Clarice McCauley | Interim General Counsel, Corporate Secretary, Vice President and Chief Compliance Officer |
| Francis T. Lo | Chief People Officer |
| Susan Bobulsky | Chief Commercial Officer of MRD |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 7, 2025 | SCHEDULE 13G/A | Filing |
| May 1, 2025 | 144 | Filing |
| May 1, 2025 | 10-Q | Quarterly Report |
| May 1, 2025 | 8-K | Current Report |
| Apr 29, 2025 | ARS | Filing |
| Apr 29, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 29, 2025 | DEF 14A | Other definitive proxy statements |
| Apr 17, 2025 | SCHEDULE 13G/A | Filing |
| Mar 24, 2025 | 144 | Filing |
| Mar 13, 2025 | 144 | Filing |